Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 7Lung Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Solid Tumors 1Adenoma, Islet Cell 1

Interventions

Temozolomide 6Capecitabine 4Everolimus 3Thalidomide 2Sunitinib 2Streptozocin 2Octreotide 2Injections 2Fluorouracil 2surufatinib 1sargramostim 1recombinant interferon alpha 2b-like protein 1nimotuzumab 1motesanib diphosphate 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1Tegafur 1Specimen Handling 1PM 01183 1Metformin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenoma, Islet Cell × PM 01183 × Clear all
NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

National Cancer Center, Korea

Phase 2 Enrolling by invitation
46 enrolled
EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡